HAINAN POLY PHARM
GenericsHAINAN POLY PHARM is a generic drug manufacturer focused on Neurology, Infectious Disease, Oncology.
HAINAN POLY PHARM's Key Drugs
HAINAN POLY PHARM's core commercial portfolio centers on CISATRACURIUM BESYLATE PRESERVATIVE FREE, spanning Neurology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
HAINAN POLY PHARM's Recent FDA Approvals
HAINAN POLY PHARM secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
HAINAN POLY PHARM's Therapeutic Areas
HAINAN POLY PHARM's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HAINAN POLY PHARM's Top Competitors
HAINAN POLY PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HAINAN POLY PHARM Pipeline Snapshot
Active clinical trials for HAINAN POLY PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CISATRACURIUM BESYLATE PRESERVATIVE FREE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-03-20
- Latest
- 2026-05-29
- Applications
- 17